These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1028 related articles for article (PubMed ID: 33312177)

  • 21. Immunotherapeutic strategies including transplantation: eradication of disease.
    Gribben JG; Riches JC
    Hematology Am Soc Hematol Educ Program; 2013; 2013():151-7. PubMed ID: 24319176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
    Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on current and prospective immunotherapies for chronic lymphocytic leukemia.
    Emole JN; Locke FL; Pinilla-Ibarz J
    Immunotherapy; 2015; 7(4):455-66. PubMed ID: 25917633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
    D'Souza P; Walker G
    Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
    Haseeb M; Anwar MA; Choi S
    Front Immunol; 2018; 9():2720. PubMed ID: 30542344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD40 activation: potential for specific immunotherapy in B-CLL.
    von Bergwelt-Baildon M; Maecker B; Schultze J; Gribben JG
    Ann Oncol; 2004 Jun; 15(6):853-7. PubMed ID: 15151939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Keating MJ
    J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
    Riches JC; Ramsay AG; Gribben JG
    Curr Pharm Des; 2012; 18(23):3389-98. PubMed ID: 22591385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapies in CLL.
    Park JH; Brentjens RJ
    Adv Exp Med Biol; 2013; 792():241-57. PubMed ID: 24014300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.
    Boyiadzis M; Foon KA; Pavletic S
    Expert Opin Biol Ther; 2007 Dec; 7(12):1789-97. PubMed ID: 18034645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic lymphocytic leukemia: new concepts for future therapy.
    Wierda WG; Chiorazzi N; Dearden C; Brown JR; Montserrat E; Shpall E; Stilgenbauer S; Muneer S; Grever M
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):369-78. PubMed ID: 21030350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
    Taghiloo S; Asgarian-Omran H
    Eur J Haematol; 2024 Jul; 113(1):4-15. PubMed ID: 38698678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic lymphocytic leukemia treatment algorithm 2018.
    Parikh SA
    Blood Cancer J; 2018 Oct; 8(10):93. PubMed ID: 30283014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
    Shadman M; Maloney DG
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):847-862. PubMed ID: 34174989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.